Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting

Informations

• Publié par: amsterdam-molecular-therapeutics-amt-b-v
• Nombre de lectures: 15
• Langue: English

Extrait

Amsterdam Molecular Therapeutics (AMT)

Holding N.V. (in liquidation) Announces

Publication of its Accounts for 2011 and Notice

of Annual General Meeting

PR Newswire

AMSTERDAM, July 13, 2012

AMSTERDAM

,

July 13, 2012

/PRNewswire/ --

Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext:

AMT) published its Annual Report and Accounts for the year ended

December

31, 2011

and announced that it will host its Annual General Meeting at its

headquarters (Meibergdreef 61, 1105 BA Amsterdam Zuidoost,

the

Netherlands

) at 14.00 hrs on

September 12, 2012

. Shareholders of the

dissolved company are invited to attend.

For further details, agenda and voting information, visit:

http://www.amtbiopharma.com/investors/shareholder-information

About Amsterdam Molecular Therapeutics (AMT)

Holding N.V. (in liquidation)

On

March 30, 2012

, an extraordinary general meeting of shareholders

approved a major corporate restructuring and financing transaction involving

the disposal of AMT's entire business and operations to uniQure B.V. and the

subsequent dissolution, liquidation and delisting of AMT. On

April 5

, the disposal

completed and AMT's dissolution as resolved by the extraordinary general

meeting of shareholders became effective, with Mr. Jörn Aldag and Mr. Piers

Morgan being appointed as the liquidators charged with the liquidation of the

company's dissolved property. On

April 26, 2012

, the liquidators made an

advance distribution - consisting of depositary receipts for ordinary class B in

uniQure B.V. - to AMT's shareholders. There will not be any further (final)

distributions made to AMT shareholders.

AMT and the AMT shares will continue to exist until the liquidation is finalised,

which is expected to occur before the end of 2012. AMT and its shares ceasing

to exist upon the ending of the liquidation shall effectively also result in the

delisting of AMT, to the extent the delisting cannot be achieved at an earlier

date in consultation with Euronext Amsterdam and subject to such conditions as

Euronext Amsterdam may propose.

Further information on AMT, can be found on AMT's website

http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements"

including those that refer to management's plans and expectations for future

operations, prospects and financial condition. Words such as "strategy,"

"expects," "plans," "anticipates," "believes," "will," "continues," "estimates,"

"intends," "projects," "goals," "targets" and other words of similar meaning are

intended to identify such forward-looking statements. Such statements are

based on current expectations only. Undue reliance should not be placed on

these statements because, by their nature, they are subject to known and

unknown risks and can be affected by factors that are beyond the control of

AMT (in liquidation). Actual results could differ materially from current

expectations due to a number of factors and uncertainties. AMT (in liquidation)

expressly disclaims any intent or obligation to update any forward-looking

statements herein except as required by law.

PRN NLD